Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Critics Urge Change In India’s Patent-Marketing Link For Drugs

This article was originally published in PharmAsia News

Executive Summary

India needs to change its patent-marketing link for drugs, preferably adopting a U.S.-Canadian model, according to critics of the current regulations. They say India needs to take steps to reassure foreign drug makers their patents will be protected in the country before and after drug approved. The central complaint is India's patent law allows challenges to the patents at both stages, and critics say the Drugs Controller General of India should cease accepting applications from others for drugs that already have patents. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts